Highly sensitive detection and mutational analysis of lung cancer circulating tumor cells using integrated combined immunomagnetic beads with a droplet digital PCR chip

Gao, Wanlei; Huang, Ting; Yuan, Haojun; Yang, Jun; Jin, Qinghui; Jia, Chunping; Mao, Guoxin; Zhao, Jianlong

doi:10.1016/j.talanta.2018.03.083

Cited by 43 publications

(32 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome this, other markers must be considered. For example, Gao and colleagues enriched lung cancer CTCs using anti-EpCAM, anti-Mucin 1(MUC1) and anti-EGFR antibodies [113]. Alternative approaches, preferable because they include EpCAM low and EpCAMpopulations, leaving CTCs unstained, involve the immunomagnetic depletion of CD45 + leukocytes [114].…”

Section: Box 2 -Strategies For Ctc Isolation Enrichment and Identifimentioning

confidence: 99%

Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

Rubis

Krishnan

Bebawy

2019

Trends in Pharmacological Sciences

440

343

View full text Add to dashboard Cite

Liquid biopsy, consisting in the non-invasive analysis of circulating tumor-derived material (the Tumor Circulome), represents an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, ctDNA and CTCs are the only components whose clinical application is FDA-cleared. Extracellular vesicles, ctRNA and tumor-educated platelets are relatively novel tumor circulome constituents with promising potential at each stage of cancer management. Here, we discuss the clinical applications of each element of the tumor circulome and the prevailing factors that currently limit implementation in clinical practice. We also detail the most recent technological developments in the field, which demonstrate potential in improving the clinical value of liquid biopsies. Commented [GDR3R2]: Thanks for doing that Commented [MK(2]: Please include all weblinks in a separate section before "References", entitled "Resources" Commented [MK(1]: Please include all weblinks in a separate section before "References", entitled "Resources" Commented [MK(4]: Since this is how it is depicted in the Figure. Commented [MK(5]: I suggest that this be converted into "Key Figure". The Figure represents the contents of the review well. Commented [MK(6]: Are the authors talking about advances in sample isolation? I'd encourage you to give examples to align the readers to what advancements the authors are referring to. Commented [GDR7R6]: Done with some of the innovations discussed in the following chapters.

show abstract

Section: Box 2 -Strategies For Ctc Isolation Enrichment and Identifimentioning

confidence: 99%

Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

Rubis

Krishnan

Bebawy

2019

Trends in Pharmacological Sciences

440

343

View full text Add to dashboard Cite

show abstract

“…Hence, finding supplemental or replacing markers for EpCAM is an alternative approach. A large number of markers, including N-Cadherin, O-Cadherin, VCAM-1, ICAM-1, CEA, CA19-9, CA72-4 61 , pepsinogens 62 , MUC1 63 , EphB4, CD44 6 , CD133, CD146, CK18, CK19 5 , Ctnnd1 64 , PSMA, HER2 45 , EGFR 65 , TROP-2, and FAPα, have been investigated for CTC detection. However, most of these markers only target certain cancer cells specifically and some markers perform similar to EpCAM in EMT.…”

Section: Current Key Challenges and Corresponding Methodsmentioning

confidence: 99%

Advances in isolation and detection of circulating tumor cells based on microfluidics

Zou

Cui

2018

Cancer Biology & Medicine

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are the cancer cells that circulate in the peripheral blood after escaping from the original or metastatic tumors. CTCs could be used as non-invasive source of clinical information in early diagnosis of cancer and evaluation of cancer development. In recent years, CTC research has become a hotspot field wherein many novel CTC detection technologies based on microfluidics have been developed. Great advances have been made that exhibit obvious technical advantages, but cannot yet satisfy the current clinical requirements. In this study, we review the main advances in isolation and detection methods of CTC based on microfluidics research over several years, propose five technical indicators for evaluating these methods, and explore the application prospects. We also discuss the concepts, issues, approaches, advantages, limitations, and challenges with an aim of stimulating a broader interest in developing microfluidics-based CTC detection technology.

show abstract

“…4,5 Due to the epithelial-tointerstitial transition, the recent CTC analysis method based on epithelial cell adhesion molecule (EpCAM) has a limited ability to detect CTCs in patients with malignant tumors. 6 We have developed a self-assembling peptide nanomicrocapsule with a lipid bilayer structure using EGFRbinding peptide derivatives (an oligopeptide composed of 11 amino acids of GE11). [7][8][9] The particle size and the content of the surface peptides can be controlled with different receptor targeting abilities in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres

Wang

Zhang

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background: This study aimed to identify an efficient, simple, and specific method of detecting mutations in the epidermal growth factor receptor (EGFR) gene in isolated lung cancer circulating tumor cells (CTCs) and to improve the ability to obtain tumor tissue clinically. Methods: EGFR peptide lipid magnetic spheres (EG-P-LMB) were prepared by reverse evaporation, and characterization and cell capture efficiency assessed. The peripheral blood samples of 30 lung cancer patients were isolated and identified with the EG-P-LMB using 20 healthy volunteers as controls. Finally, the isolated CTCs were tested for EGFR gene mutations, and the tissue samples selected for comparison. Results: The prepared magnetic spheres had a smaller particle size and higher stability according to the particle size potential test. Their morphology was homogeneous by atomic force observation, and the UV test showed that there were peptides on the surface. The separation efficiency of EG-P-LMB was greater than 90% in PBS and greater than 80% in the blood simulation system. Compared with the tissue sample results, the positive rate of EGFR gene mutations was 94%. The CTC test results of 27 patients were consistent with the tissue test results of the corresponding patients, and the consistency with the tissue comparison test results was 90% (27/30). Conclusions: EG-P-LMB can effectively capture CTCs in the peripheral blood of patients with lung cancer. CTC detection can accurately identify mutations in the EGFR gene and improve the ability to obtain tumor tissue in clinical practice.

show abstract

Highly sensitive detection and mutational analysis of lung cancer circulating tumor cells using integrated combined immunomagnetic beads with a droplet digital PCR chip

Cited by 43 publications

References 32 publications

Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

Advances in isolation and detection of circulating tumor cells based on microfluidics

Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres

Contact Info

Product

Resources

About